A phenome-wide hunt for risk factors of Alzheimer’s disease: from metabolic clues to neuroimaging evidence

Read full text
Authors: Dongming Liu, Ancha V. Baranova, Wenxi Sun, Hongbao Cao, Bing Zhang, Fuquan Zhang, Alzheimer’s Disease Neuroimaging Initiative
Cited by: 0
References: 58

Abstract

BACKGROUND: This study systematically investigated phenotypes causally associated with Alzheimer's disease (AD) across the phenome and validated the findings at cognitive and neuroimaging levels using real-world clinical data. METHODS: We performed phenome-wide Mendelian Randomization (MR) analyses on genetic proxies for over 860 disease phenotypes to identify traits causally associated with AD. Lipid metabolism-related phenotypes identified through MR were further examined in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset to assess associations with AD risk, brain structure, and cognition. RESULTS: MR analyses revealed a significant causal association between lipid metabolism, particularly low-density lipoprotein cholesterol (LDL-C), and the risk of AD (OR: 1.05, 95% CI: 1.03-1.07). In ADNI, higher LDL-C indicators correlated with increased AD risk, reduced hippocampal and entorhinal volumes, and poorer cognitive performance. Notably, elevated cholesterol-to-total lipid ratios in small LDL particles were negatively associated with the entorhinal-hippocampal complex. Among cognitively normal individuals, higher LDL-C indicators were associated with smaller hippocampus-amygdala transition area (HATA) and CA3 head volumes. In those with mild cognitive impairment, higher LDL-C was associated with reduced entorhinal surface area. CONCLUSIONS: Our findings suggest that disrupted LDL-C metabolism may play a causal role in the development and progression of AD.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Genetic Associations and Epidemiology

Publication details

Journal / source
Journal of Translational Medicine
Volume
24
Issue
1
Publication date
5 February 2026
Language
EN